Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| China Tegafur, Gimeracil and Oteracil (Tegafur/gimeracil/oteracil) Market Report 2015-2019 | ||
| By: PR Newswire Association LLC. - 03 Sep 2015 | Back to overview list |
|
DUBLIN, Sept. 3, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/srnlnc/investigation) has announced the addition of the "Investigation Report on China Tegafur, Gimeracil and Oteracil (Tegafur/gimeracil/oteracil) Market, 2010-2019" report to their offering. Tegafur, gimeracil and oteracil (Tegafur/gimeracil/oteracil), a fluorouracil derivative, is an oral biological anti- cancer agent made up of tegafur (FT), gimeracil (CDHP) and oteracil (Oxo). In 1999, it was approved to treat advanced gastric cancer and then such indications as head and neck neoplasm, inoperable or unresectable breast cancer, non- small cell carcinoma, colon cancer, pancreatic cancer and bile duct cancer. Years of clinical application prove that tegafur, gimeracil and oteracil is a safe and effective anti- cancer drug. According to statistics, over 80% of advanced gastric cancer patients use tegafur, gimeracil and oteracil in chemotherapy, CR + PR reaching 44.6%. According to CRI's statistics, tegafur, gimeracil and oteracil develops fast after entering China with annual sales rising from less than CNY 20 million in 2009 to CNY 707 million in 2014 and CAGR reaching up to 110% during the period of 2009- 2014, which demonstrats a bright future. Tegafur, gimeracil and oteracil enjoys a vast demand in China. Currently, tegafur, gimeracil and oteracil in the Chinese market come from the following four companies: Shandong New Time Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group Corporation, Qilu Pharmaceutical Co., Ltd, Taiho Pharmaceutical Co., Ltd and Jiangsu Hengrui Medicine Co., Ltd, among which Shandong New Time Pharmaceutical Co., Ltd has the largest market share of nearly 50% with sales reaching up to CNY 348 million in 2014. Key Topics Covered: 1 Related Concepts of Tegafur, Gimeracil and Oteracil 2 Market Profile of Tegafur, Gimeracil and Oteracil in China 3 Survey on Sales Status of Tegafur, Gimeracil and Oteracil in China, 2010-2014 4 Survey on Market Share of Major Manufactures of Tegafur, Gimeracil and Oteracil in China, 2010-2014 5 Survey on Dosage Forms of Tegafur, Gimeracil and Oteracil in China, 2010-2014 6 Reference Price of Tegafur, Gimeracil and Oteracil in Chinese Hospitals in 2014 7 Major Manufacturers of Tegafur, Gimeracil and Oteracil in the Chinese Market, 2010-2014 8 Market Outlook of Tegafur, Gimeracil and Oteracil in China, 2015-2019 Companies Mentioned - Jiangsu Hengrui Medicine Co., Ltd - Lunan Pharmaceutical Group Corporation - Qilu Pharmaceutical Co., Ltd - Shandong New Time Pharmaceutical Co., Ltd., - Taiho Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/srnlnc/investigation Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net
SOURCE Research and Markets 
|
||
|
||
 | Back to overview list | |